In the primary analysis of the phase 2 CITYSCAPE trial, the TIGIT inhibitor tiragolumab plus atezolizumab (anti-PD-L1) showed improvement in PFS (stratified HR, 0.58; 95% CI, 0.38–0.89) in PD-L1-positive NSCLC patients (277). The gene discussed is CD274; the disease is non-small cell lung carcinoma.